Dosimetry after peptide receptor radionuclide therapy: impact of reduced number of post-treatment studies on absorbed dose calculation and on patient management

被引:27
|
作者
Chicheportiche, Alexandre [1 ]
Ben-Haim, Simona [1 ,2 ]
Grozinsky-Glasberg, Simona [3 ]
Oleinikov, Kira [3 ]
Meirovitz, Amichay [4 ,5 ]
Gross, David J. [3 ]
Godefroy, Jeremy [1 ]
机构
[1] Hadassah Hebrew Univ Med Ctr, Dept Nucl Med & Biophys, IL-91120 Jerusalem, Israel
[2] Univ Coll London Hosp, Inst Nucl Med, London, England
[3] Hadassah Hebrew Univ Med Ctr, Dept Endocrinol & Metab, ENETS Ctr Excellence, Neuroendocrine Tumor Unit, IL-91120 Jerusalem, Israel
[4] Hadassah Hebrew Univ Med Ctr, Dept Oncol, IL-91120 Jerusalem, Israel
[5] Hadassah Hebrew Univ Med Ctr, Radiat Therapy Unit, IL-91120 Jerusalem, Israel
关键词
Peptide receptor radionuclide therapy (PRRT); Lu-177]-DOTA-TATE; Dosimetry; SPECT; CT; INDIVIDUALIZED DOSIMETRY; KIDNEY DOSIMETRY; NORMAL TISSUE; BONE-MARROW; LU-177-DOTATATE; TOXICITY; LU-177; STANDARDIZATION; NEPHROTOXICITY; PRRT;
D O I
10.1186/s40658-020-0273-8
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Background After each cycle of [Lu-177]-DOTA-TATE peptide receptor radionuclide therapy (PRRT) dosimetry is performed to enable precise calculation of the radiation-absorbed dose to tumors and normal organs. Absorbed doses are routinely calculated from three quantitative single-photon emission computed tomography (SPECT) studies corrected by computed tomography (CT) acquired at t(1) = 24 h, t(2) = 96 h, and t(3) = 168 h after the first cycle of treatment. After following cycles, a single SPECT/CT study is performed. The aim of the present study is to assess the feasibility of a "two time point" quantitative SPECT/CT protocol after the first PRRT cycle and its impact on patient management. Quantitative SPECT/CT data of 25 consecutive patients with metastatic neuroendocrine tumors after PRRT were retrospectively analyzed. Radiation-absorbed doses calculated using the standard protocol with three SPECT/CT studies acquired at (t(1), t(2), t(3)) were compared to those obtained from three different "two time point" protocols with SPECT/CT studies performed at (t(1), t(2)), (t(1), t(3)), or (t(2), t(3)). Results The best agreement for the cumulative doses absorbed by the kidneys, bone marrow, liver, spleen, and tumors with the conventional protocol was obtained with the (t(1), t(3)) protocol with mean relative differences of - 1.0% +/- 2.4%, 0.4% +/- 3.1%, - 0.9% +/- 4.0%, - 0.8% +/- 1.1%, and - 0.5% +/- 2.0%, respectively, and correlation coefficients of r = 0.99 for all. In all patients, there was no difference in the management decision of whether or not to stop PRRT because of unsafe absorbed dose to risk organs using either the standard protocol or the (t(1), t(3)) protocol. Conclusion These preliminary results demonstrate that dosimetry calculations using two quantitative SPECT/CT studies acquired at 24 and 168 h after the first PRRT cycle are feasible and are in good agreement with the standard imaging protocol with no change in patient management decisions, while enabling improved patient comfort and reduced scanner and staff time.
引用
收藏
页数:15
相关论文
共 7 条
  • [1] Dosimetry after peptide receptor radionuclide therapy: impact of reduced number of post-treatment studies on absorbed dose calculation and on patient management
    Alexandre Chicheportiche
    Simona Ben-Haim
    Simona Grozinsky-Glasberg
    Kira Oleinikov
    Amichay Meirovitz
    David J. Gross
    Jeremy Godefroy
    EJNMMI Physics, 7
  • [2] Comparison of different calculation techniques for absorbed dose assessment in patient specific peptide receptor radionuclide therapy
    Finocchiaro, Domenico
    Berenato, Salvatore
    Bertolini, Valentina
    Castellani, Gastone
    Lanconelli, Nico
    Versari, Annibale
    Spezi, Emiliano
    Iori, Mauro
    Fioroni, Federica
    Grassi, Elisa
    PLOS ONE, 2020, 15 (08):
  • [3] CALCULATION OF ABSORBED DOSE DUE TO THE 90Y-DOTATOC PEPTIDE RECEPTOR RADIONUCLIDE THERAPY BY MCNP5/X
    Jeremic, Marija Z.
    Matovic, Milovan D.
    Pantovic, Suzana B.
    Nikezic, Dragoslav R.
    Krstic, Dragana Z.
    NUCLEAR TECHNOLOGY & RADIATION PROTECTION, 2018, 33 (04): : 380 - 385
  • [4] The comparison of serial SPECT-CT imaging to estimate absorbed dose to the organ at risk from peptide receptor radionuclide therapy dosimetry
    Bin Said, Mohamad Aminudin
    Razak, Hairil Rashmizal Bin Abdul
    Musarudin, Marianie
    IRANIAN JOURNAL OF NUCLEAR MEDICINE, 2021, 29 (01): : 2 - 7
  • [5] Optimization of the number of post-therapeutic planar imaging time points for the most reliable organ and tumour dosimetry in peptide receptor radionuclide therapy
    Konuparamban, Acsah
    Nautiyal, Amit
    Jha, Ashish Kumar
    Mithun, Sneha
    Srichandan, Tusharkanta
    Puranik, Ameya
    Rangarajan, Venkatesh
    HEALTH AND TECHNOLOGY, 2024, 14 (04) : 799 - 815
  • [6] Accurate dosimetry in 131I radionuclide therapy using patient-specific, 3-dimensional methods for SPECT reconstruction and absorbed dose calculation
    Dewaraja, YK
    Wilderman, SJ
    Ljungberg, M
    Koral, KF
    Zasadny, K
    Kaminiski, MS
    JOURNAL OF NUCLEAR MEDICINE, 2005, 46 (05) : 840 - 849
  • [7] Nephrotoxicity and hematotoxicity one year after four cycles of peptide receptor radionuclide therapy (PRRT) and its impact on future treatment planning. A retrospective analysis
    Nilica, B.
    Svirydenka, A.
    Fritz, J.
    Bayerschmidt, S.
    Kroiss, A. S.
    Gruber, L.
    Virgolini, I. J.
    REVISTA ESPANOLA DE MEDICINA NUCLEAR E IMAGEN MOLECULAR, 2022, 41 (03): : 138 - 145